Loading…
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $616M | $134M | $447M | $-25M | 69.0% | 87.3% | 1812.4% |
| 2024 | $329M | $50M | $23M | $-41M | 10.5% | 40.8% | 84.5% |
| 2023 | $234M | $26M | $13M | $-31M | 7.9% | 8290.0% | -105.7% |
| 2022 | $3M | $-213M | $-224M | $-176M | -382.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2.78 | 233.66 | 329 | 616.29 |
| Cost Of Revenue | - | 0.26 | 14.13 | 38.49 | 100.71 |
| Gross Profit | - | 2.52 | 219.53 | 290.52 | 515.57 |
| Operating Expense | - | 220.84 | 198.90 | 248.59 | 392.25 |
| Operating Income | - | -218.32 | 20.63 | 41.93 | 123.32 |
| EBITDA | - | -213.11 | 26.10 | 49.90 | 134.36 |
| EBIT | - | -213.62 | 25.68 | 49.62 | 134.12 |
| Pretax Income | - | -223.81 | 13.06 | 25.59 | 107.39 |
| Tax Provision | - | 0 | 0.39 | 2.21 | -339.79 |
| Net Income | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income Common Stockholders | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Total Expenses | - | 221.10 | 213.03 | 287.08 | 492.96 |
| Interest Expense | - | 10.19 | 12.62 | 24.03 | 26.73 |
| Research And Development | - | 125.35 | 76.19 | 94.29 | 160.22 |
| Selling General And Administration | - | 95.48 | 122.71 | 154.30 | 232.03 |
| Normalized EBITDA | - | -213.11 | 26.10 | 49.90 | 134.36 |
| Normalized Income | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Market Cap | 5,847.78 | 5,847.78 | 5,847.78 | 5,847.78 | 5,847.78 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TG Therapeutics, Inc.this co. | TGTX | $5.3B | 13.08↓ discount | 9.02 | 69.0% | 44.82 |
| Alkermes plc | ALKS | $5.5B | 22.97 | 3.05 | 13.3% | 15.81 |
| PTC Therapeutics, Inc. | PTCT | $5.4B | 8.29 | -27.55 | -332.5% | 8.31 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.1B | 233.78 | 14.14 | 6.0% | 74.89 |
| Corcept Therapeutics Incorporated | CORT | $4.8B |
| - |
| - |
| - |
| - |
| - |
| 49.62 |
| 7.63 |
| 15.4% |
| 103.46 |
| Waystar Holding Corp. | WAY | $4.5B | 43.50 | 1.26 | 2.9% | 16.17 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.2B | 19.29 | -40.92 | -212.1% | 13.84 |
| Merit Medical Systems, Inc. | MMSI | $4.1B | 31.84 | 2.58 | 8.1% | 13.45 |
| Amneal Pharmaceuticals, Inc. | AMRX | $3.9B | 55.43 | -56.42 | -101.8% | 10.60 |
| Peer Median | - | 37.67 | 1.92 | 4.5% | 14.83 | |